Cognition Therapeutics Reports Positive Phase 2 Study Results for CT1812 in Dementia with Lewy Bodies

Stock Information for Cognition Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cognition Therapeutics Inc.

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)
Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics Releases New Episode of "Conversations" Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.